Skip to Content
Merck
CN
  • Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature.

Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature.

The neurologist (2012-01-06)
Zvi Kamenetsky, Nael Da'as, Yaacov Esayag, Yosef Kleinman, Noah Samuels
ABSTRACT

We present a case of eosinophilic pleural effusion due to valproic acid (VPA), a rare adverse event that has been reported previously. A 30-year-old male patient presented with respiratory symptoms and right-sided pleuritic pain, within days of initiation of VPA treatment for a generalized seizure. Chest radiography revealed a moderate-sized right-sided pleural effusion, which was an exudate with a pH of 7.54 and 48% eosinophils. Symptoms resolved soon after discontinuation of the drug, as did the effusion in a repeat radiograph 3 weeks later. The likelihood that VPA was the cause of the effusion is examined.

MATERIALS
Product Number
Brand
Product Description

Supelco
Valproic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-Propylpentanoic acid
Valproic acid, European Pharmacopoeia (EP) Reference Standard
USP
Valproic acid, United States Pharmacopeia (USP) Reference Standard
Supelco
Valproic acid solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®